Current Perspectives in Assessing Humoral Immunity After Measles Vaccination

Overview

Journal Expert Rev Vaccines

Date 2018 Dec 27

PMID 30585753

Citations 22

Authors

Iana H Haralambieva

Richard B Kennedy

Inna G Ovsyannikova

Daniel J Schaid

Gregory A Poland

Affiliations

Soon will be listed here.

Abstract

Introduction: Repeated measles outbreaks in countries with relatively high vaccine coverage are mainly due to failure to vaccinate and importation; however, cases in immunized individuals exist raising questions about suboptimal measles vaccine-induced humoral immunity and/or waning immunity in a low measles-exposure environment.

Areas Covered: The plaque reduction neutralization measurement of functional measles-specific antibodies correlates with protection is the gold standard in measles serology, but it does not assess cellular-immune or other parameters that may be associated with durable and/or protective immunity after vaccination. Additional correlates of protection and long-term immunity and new determinants/signatures of vaccine responsiveness such as specific CD46 and IFI44L genetic variants associated with neutralizing antibody titers after measles vaccination are under investigation. Current and future systems biology studies, coupled with new technology/assays and analytical approaches, will lead to an increasingly sophisticated understanding of measles vaccine-induced humoral immunity and will identify 'signatures' of protective and durable immune responses.

Expert Opinion: This will translate into the development of highly predictive assays of measles vaccine efficacy, effectiveness, and durability for prospective identification of potential low/non-responders and susceptible individuals who require additional vaccine doses. Such new advances may drive insights into the development of new/improved vaccine formulations and delivery systems.

Citing Articles

Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity.

Emmelot M, Bodewes R, Maissan C, Vos M, de Swart R, van Els C NPJ Vaccines. 2025; 10(1):36.

PMID: 39979288 PMC: 11842548. DOI: 10.1038/s41541-025-01088-y.

Measles surveillance data analysis and serological survey in Quzhou, China, 2014-2024: an assessment of progress toward measles elimination.

Gong X, Zheng W, Lai S, Yin Z Front Med (Lausanne). 2024; 11:1492873.

PMID: 39564511 PMC: 11573565. DOI: 10.3389/fmed.2024.1492873.

Serosurveillance for Measles and Rubella.

Brady A, El-Badry E, Padron-Regalado E, Escudero Gonzalez N, Joo D, Rota P Vaccines (Basel). 2024; 12(7).

PMID: 39066453 PMC: 11281569. DOI: 10.3390/vaccines12070816.

Seroprevalence of Measles (Rubeola) Antibodies in Childhood Cancer Survivors.

Crom D, Walters L, Li Y, Liang J, Hijano D, Mulrooney D J Pediatr Hematol Oncol Nurs. 2024; 41(5):309-314.

PMID: 38715372 PMC: 11612261. DOI: 10.1177/27527530231221145.

Early B cell transcriptomic markers of measles-specific humoral immunity following a 3 dose of MMR vaccine.

Haralambieva I, Chen J, Quach H, Ratishvili T, Warner N, Ovsyannikova I Front Immunol. 2024; 15:1358477.

PMID: 38633249 PMC: 11021587. DOI: 10.3389/fimmu.2024.1358477.

References

. Notes from the field: Multiple cases of measles after exposure during air travel--Australia and New Zealand, January 2011. MMWR Morb Mortal Wkly Rep. 2011; 60(25):851. View

Zhu Z, Zhang F, Hu H, Bakshi A, Robinson M, Powell J . Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016; 48(5):481-7. DOI: 10.1038/ng.3538. View

Oberg A, McKinney B, Schaid D, Pankratz V, Kennedy R, Poland G . Lessons learned in the analysis of high-dimensional data in vaccinomics. Vaccine. 2015; 33(40):5262-70. PMC: 4581898. DOI: 10.1016/j.vaccine.2015.04.088. View

de Swart R, de Vries R, Rennick L, van Amerongen G, McQuaid S, Verburgh R . Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection. NPJ Vaccines. 2017; 2:22. PMC: 5627256. DOI: 10.1038/s41541-017-0022-8. View

Edens C, Collins M, Goodson J, Rota P, Prausnitz M . A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015; 33(37):4712-8. PMC: 4554796. DOI: 10.1016/j.vaccine.2015.02.074. View

Buchholz C, Schneider U, Devaux P, Gerlier D, Cattaneo R . Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol. 1996; 70(6):3716-23. PMC: 190247. DOI: 10.1128/JVI.70.6.3716-3723.1996. View

Joyce J, Carroll T, Collins M, Chen M, Fritts L, Dutra J . A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques. J Infect Dis. 2018; 218(1):124-132. PMC: 5989599. DOI: 10.1093/infdis/jiy139. View

Cattaneo R . Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol. 2004; 78(9):4385-8. PMC: 387720. DOI: 10.1128/jvi.78.9.4385-4388.2004. View

Griffin D . The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses. 2016; 8(10). PMC: 5086614. DOI: 10.3390/v8100282. View

10.

Haralambieva I, Ovsyannikova I, Pankratz V, Kennedy R, Jacobson R, Poland G . The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Expert Rev Vaccines. 2012; 12(1):57-70. PMC: 3570049. DOI: 10.1586/erv.12.134. View

11.

Nakaya H, Wrammert J, Lee E, Racioppi L, Marie-Kunze S, Nicholas Haining W . Systems biology of vaccination for seasonal influenza in humans. Nat Immunol. 2011; 12(8):786-95. PMC: 3140559. DOI: 10.1038/ni.2067. View

12.

Latner D, McGrew M, Williams N, Lowe L, Werman R, Warnock E . Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. Clin Vaccine Immunol. 2010; 18(1):35-42. PMC: 3019787. DOI: 10.1128/CVI.00284-10. View

13.

Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000; 406(6798):893-7. DOI: 10.1038/35022579. View

14.

Christenson B, BOTTIGER M . Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 1994; 12(2):129-33. DOI: 10.1016/0264-410x(94)90049-3. View

15.

Whitaker J, Poland G . Measles and mumps outbreaks in the United States: Think globally, vaccinate locally. Vaccine. 2014; 32(37):4703-4. DOI: 10.1016/j.vaccine.2014.06.088. View

16.

Clifford H, Hayden C, Khoo S, Naniche D, Mandomando I, Zhang G . Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique. Vaccine. 2012; 30(43):6180-5. DOI: 10.1016/j.vaccine.2012.07.063. View

17.

McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood A, Teumer A . A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016; 48(10):1279-83. PMC: 5388176. DOI: 10.1038/ng.3643. View

18.

Choileain S, Hay J, Thomas J, Williams A, Vermeren M, Benezech C . TCR-stimulated changes in cell surface CD46 expression generate type 1 regulatory T cells. Sci Signal. 2017; 10(502). DOI: 10.1126/scisignal.aah6163. View

19.

Peterson V, Zhang K, Kumar N, Wong J, Li L, Wilson D . Multiplexed quantification of proteins and transcripts in single cells. Nat Biotechnol. 2017; 35(10):936-939. DOI: 10.1038/nbt.3973. View

20.

Pannuti C, Morello R, de Moraes J, Curti S, Afonso A, Camargo M . Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol. 2004; 11(1):119-22. PMC: 321355. DOI: 10.1128/cdli.11.1.119-122.2004. View